As­traZeneca and Am­gen qui­et­ly ad­mit teze­pelum­ab set­back as the Dupix­ent chal­lenger heads to FDA

As­traZeneca and Am­gen have block­buster am­bi­tions for their teze­pelum­ab an­ti­body, aim­ing to chal­lenge the Re­gen­eron and Sanofi gi­ant Dupix­ent in asth­ma and re­lat­ed res­pi­ra­to­ry mal­adies. But as part of its sec­ond quar­ter up­date Thurs­day morn­ing, the big British drug­mak­er qui­et­ly scut­tled plans in an­oth­er in­di­ca­tion, rais­ing doubt over how big a bite it will take out of the Dupix­ent pie.

Af­ter flunk­ing two Phase II stud­ies in atopic der­mati­tis, As­traZeneca dropped plans for teze­pelum­ab to treat the con­di­tion al­to­geth­er, the com­pa­ny re­vealed Thurs­day morn­ing. The move comes just a few weeks af­ter the an­ti­body won pri­or­i­ty re­view from the FDA in asth­ma, where a de­ci­sion is ex­pect­ed in the first quar­ter next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER